Table 2 Concentration and frequency of β-thymosins in scleroderma patients and controls.
From: β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up
46 scleroderma pts | 15 controls | |
|---|---|---|
presence of Tβ4, n pts (%) | 46 (100%) | 15 (100%) |
Tβ4 (μmol/L, mean ± SD) | 0.310 ± 0.372* | 0.112 ± 0.084 |
(median, range) | (0.21, 0-2.1) | (0.09, 0-0.26) |
presence of sTβ4, n pts (%) | 14 (30%) | 5 (33%) |
sTβ4 (μmol/L, mean ± SD) | 0.016 ± 0.041 | 0.007 ± 0.011 |
(median, range) | (0,0-0.24) | (0.01, 0-0.08) |
presence of Tβ10, n pts (%) | 28 (60.9%) | 8 (53.3%) |
Tβ10 (μmol/L, mean ± SD) | 0.050 ± 0.072 | 0.017 ± 0.022 |
(median, range) | (0.02, 0-0.3) | (0, 0-0.04) |
Tβ4/sTβ4 ratio (mean ± SD) | 9.4 ± 2.6 | 11.0 ± 4.6 |